Researchers examined whether menopausal symptoms, quality of life, and depression are related to arterial stiffness, a risk factor for cardiovascular disease.
Researchers examined the effect of menopausal hormone therapy on left ventricular and left atrial chamber structure and function changes, which are markers of subclinical cardiovascular disease.
Physicians should be aware that the benefit of menopausal hormone therapy (MHT) on body composition might rapidly disappear after its withdrawal and strongly encourage women to optimize nutrition and increase physical activity when stopping MHT.
Researchers assessed the effects of 2 frequently used formulations of menopausal hormone therapy on brain structure and cognition 3 years after the completion of a randomized clinical trial.
At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.
Researchers conducted a prospective, population-based cohort study to assess the risk for cardiovascular disease in postmenopausal women with increased androgen levels.
Oral micronized progesterone may diminish hot flushes and night sweats in perimenopausal women, according to research presented at ENDO 2018.
Researchers examined the correlation between Cobb angle of kyphosis from lateral spine radiographs and pattern of self-reported menopausal hormone therapy use.
Researchers observed detrimental effects of RYGB on bone turnover, mass, structure, and strength just 6 months postoperatively, and these effects persisted throughout the duration of the 12-month study.
A nonhormonal treatment option for the relief of symptoms associated with menopause is now available alongside other drug-free supplements.
The use of hormone therapy up to 5 years after onset of menopause is associated with a lower risk for ischemic and hemorrhagic stroke compared with late hormone therapy initiation or no hormone therapy use.
To update its 2012 recommendation, the US Preventive Services Task Force reviewed evidence on the benefits and harms of systemic hormone therapy for the prevention of chronic conditions in postmenopausal women.
Findings indicate that using a BMI cutpoint of 30 may lead to bias in measuring the effects of obesity on health outcomes in postmenopausal women.
There may be other roles of estradiol therapy besides relief from menopause-related symptoms, including limiting effects of stress on working memory.
Underweight women have a significantly greater risk of experiencing early menopause compared with lean or overweight women.
Increased mortality risks were limited to the first post-HT year because increases in risks markedly decreased when the follow-up time was extended over more than 1 year.
No other randomized clinical trial of hormone therapy has been large enough to assess a potential modifying effect of age on all-cause mortality, and most previous trials of chronic disease outcomes have focused on older women.
Rates of cBHT prescriptions are not yet being systemically tracked, and few data exist to demonstrate the safety, efficacy, or utility of the treatment.
Lifestyle modification and an individualized treatment approach are effective strategies for managing menopausal symptoms in breast cancer survivors who are largely advised to avoid hormone replacement therapy.
The Female Sexual Functioning Index was used to assess aspects of sexual function and experience in early postmenopausal women.
According to a study published in the Journal of Bone and Mineral Research, researchers hypothesized that serum K-Postn levels may be able to predict low-trauma fractures.
Intrarosa, the first FDA approved local, non-estrogen product for treating dyspareunia, is now available.
Although the updated statement does not change the recommendations outlined in previous treatment guidelines, the authors have added 8 new recommendations based on evidence that has emerged in the interim.
A combination of early menstruation with more frequent periods may lower a woman's depression risk.
Acute decline in ovarian function may contribute to the autoimmunity associated with rheumatoid arthritis.
The North American Menopause Society released updated guidelines for hormone therapy use in women who are postmenopausal.
Long-term denosumab increased bone mineral density in postmenopausal women.
Age significantly affected the association between hot flash status and flow-mediated dilation, particularly in younger women.
The fewer menstrual cycles women had over a lifetime placed them at greater risk for incident heart failure.
Research results indicate that more randomized clinical trials are needed to examine the relationship between hearing loss and oral hormone replacement therapy.
After 24 months, bone mineral density was statistically different from baseline.
Serum samples, spirometry, and questionnaire data were collected from nearly 1500 women to determine if menopausal status affected lung function.
Findings in postmenopausal women with T2DM; correlations prominent in those with higher 25(OH)D
Researchers examined body mass index differences in current, past, and never users of menopausal hormone therapy.
HRT in postmenopausal women was linked to lower CAC scores and a lower risk of long-term, all-cause mortality.
Severe anxiety was independently associated with poor quality of life in postmenopausal patients.
Data from the Nurses' Health Studies were analyzed to determine if there is a link between seropositive and seronegative rheumatoid arthritis and age of menopause onset.
For women with HIV, anti-Müllerian hormone is associated with age of menopause onset.
Women in the menopausal transition and early postmenopause are at higher risk for depressive symptoms and negative mood than those in late postmenopause.
Menopausal status is associated with accelerated lung function decline.
The FDA recently approved Intrarosa (prasterone) for moderate to severe pain during sexual intercourse due to menopause.
The use of menopausal hormone therapy was associated with improved bone mineral density and better bone microarchitecture.
Half of women treated with acupuncture report a decline in the frequency of menopausal vasomotor symptoms, according to a study published in Menopause.
Although a majority of women reported sexual satisfaction, many felt that it could improve.
Many women are able to adapt to the negative changes in sexual function that they experience as they age.
After 10 years follow-up, researchers found that women who experienced surgical menopause were more likely to suffer worse insomnia symptoms.
Nearly 2000 women underwent screening to determine if a link exists between depression or depressive symptoms and coronary artery disease.
Both peri- and postmenopausal women were assessed to find a relationship between sleep time, sleep quality, and carotid atherosclerosis.
During menopause, women who experience more hot flashes at night are more likely to experience worsening mood.
Women who enter menopause before age 45 had a 50% greater risk for cardiovascular disease as well as an increased risk for cardiovascular death.
For postmenopausal women, soy isoflavone supplementation is associated with improvement in bone health.
African-American women in particular experienced more rapid progression in metabolic syndrome severity during pre- and perimenopausal periods compared to post-menopausal period.
The Women's Health Initiative found that women's reproductive history is associated with risk of type 2 diabetes.
An index accounting for both bone formation and resorption may help identify which women may experience faster bone loss during menopause.
Researchers identified 4 distinct trajectories of vasomotor symptoms predicted by reproductive hormones, race and ethnicity, BMI, and psychosocial characteristics.
In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.
The review shows modest reductions in frequency of hot flashes and vaginal dryness, but not in night sweats.
Moderate-quality evidence shows a reduction in the frequency of hot flashes with paroxetine.
Investigational drug improved vaginal cells and vaginal pH at all dose levels.
Duration of estrogen deficiency in women with nonalcoholic fatty liver disease may be more likely to have severe fibrosis.
More than 20% of women currently using hormone replacement therapy experienced an increase in migraine severity.
Postmenopausal women whose last pregnancy occurred at 40 years of age or older may have a greater risk of hemorrhagic stroke.
Sedentary lifestyles were common among middle-aged Hispanic women and were also associated with worse menopausal symptoms.
An individualized approach based on patient preferences is important for treatment of menopause.
Noninsertive sham acupuncture is a superior treatment option for menopausal women with hot flashes compared to Chinese medicine acupuncture.
Recent data suggest that older age at menopause as well as a longer reproductive period have a lower risk for depression later in life.
For postmenopausal women, suppositories containing the hormone dehydroepiandrosterone (DHEA) may reduce vaginal dryness, discomfort, and pain during sex without raising overall estrogen levels.
Active smoking and secondhand smoke exposure increases the risk for infertility and natural menopause before age 50.
Common vulvovaginal symptoms can have emotional, lifestyle, and sexual effects in postmenopausal women.
Follicle-stimulating hormone may interact with its receptors and lead to elevated LDL cholesterol in postmenopausal women.
An increased risk was seen with late age at natural menopause and with any use of menopausal hormone therapy.
Symptoms during the menopausal transition appear to be worse in women with HIV.
Increased HDL cholesterol during menopausal transition linked to greater carotid intima-media thickness.
Postmenopausal women experienced increased muscle strength, less muscle mass loss with vitamin D supplements.
Postmenopausal women with insomnia experienced less sexual satisfaction and frequency.
Initiating hormone therapy earlier in menopause may lower risk for later development of coronary heart disease.
One-third of women taking hormone therapy at menopause are using compounded hormones.
Women who reported recent abuse experienced more bother from menopausal symptoms.
Women demonstrate preference for oral estrogens for genitourinary menopausal symptoms.
Vaginal estrogen may provide numerous medical benefits without system side effects for women post menopause.
Women seeking relief from menopausal symptoms must be aware of the risks, benefits of different treatment options.
Peri- and postmenopausal women have a greater volume of fat around their hearts than premenopausal women.
There are larger differences in nonfatal events seen for whites vs. blacks, but risk for death not affected by race.
Risk remains high over several years.
Women in early menopause are more likely to experience sleep disruptions throughout menstrual cycle.
Randomized trial shows beneficial effect for yoga combined with meditation in breast cancer survivors.
Small study suggests lisdexamfetamine might help with concentration and thought organization.
Increased odds of seropositivity in women with menopause aged younger than 45 years vs. 45 years or older.
Researchers found no difference between women who took supplements and those who didn't.
No difference in incidence of upper GI bleeding in menopausal hormone therapy users vs. non-users.
Postmenopausal women using hormone therapy with statins may have a reduced risk for all-cause mortality.
Experiencing hot flashes earlier in life appears to be linked to poorer endothelial function in women.
Another study looking at the potential dangers of hormone replacement therapy for menopausal symptoms suggests the treatment yields no cardiovascular benefit.
As many as 86% of women taking hormones for menopause are using compounded, "bioidentical" hormones without understanding the risks.
More than half of women experience these symptoms for 7 years or more.
Even a few years of use increases cancer risk.
Menopausal symptoms, including hot flashes and insomnia, were reduced after receiving a noninvasive neurotechnology.
Menstrual abnormalities, endometriosis, pelvic pain, early menopause associated with the disorder.
Women with high levels of exposure to endocrine-disrupting chemicals may experience menopause earlier than those with lower levels.
Study of postmenopausal women suggests hormone levels matter more than excess weight.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Vascular Mortality Declining in Adults With Diabetes in the United States
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- Preventing Hypoglycemia During Exercise in Type 1 Diabetes on CSII
- Implantable Continuous Glucose Monitoring Device Safe, Effective for Adolescents
- First CGM System With Implantable Glucose Sensor Approved
- Treatment for Necrobiosis Lipoidica Gets Orphan Drug Designation
- Intensified, Multifactorial Intervention for Type 2 Diabetes Reduces Risk for Heart Failure